Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of 5 drugs targets tough leukemia

NCT ID NCT00801489

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal is to see how well the treatment works and what side effects it causes. The drugs work together to kill cancer cells and help the immune system recover from chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, idarubicin

What this could lead to

If this works, it could offer a more effective treatment option for people with certain genetic types of acute myeloid leukemia or high-risk myelodysplastic syndrome.

What could go wrong

This is a phase 2 trial, so it's still early. The combination of drugs may cause severe side effects, and it's not yet known if it will improve survival compared to standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with t(6;9)(p23;q34) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myeloid leukemia, t(8;21)(q22; q22.1) chromosome inversion disorder Leukemia, Myelomonocytic, Acute myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA WITH INV(16)(P13.1Q22); CBFB-MYH11 ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11 ACUTE MYELOID LEUKEMIA WITH T(8;21); (Q22; Q22.1); RUNX1-RUNX1T1 DE NOVO MYELODYSPLASTIC SYNDROME HIGH RISK MYELODYSPLASTIC SYNDROME INV(16) MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS T(16;16) T(8;21) UNTREATED ADULT ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

    Contact